About Merus Labs
Merus Labs was established in 2009 in Toronto, Canada, within the pharmaceuticals sector. Corporate growth is pursued through an opportunistic product acquisition strategy. The portfolio encompasses Sintrom for thromboembolic conditions, Enablex for overactive bladder, Salagen for radiation-induced dry mouth, and Vancocin capsules for bacterial infections like C. difficile. Operations focus on sourcing and integrating these treatments for womens health, cancer, infectious, and cardiovascular areas.
- Headquarter Toronto, Canada
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Merus Labs
Investors in Merus Labs
Merus Labs has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Norgine, PDL BioPharma and PowerOne Capital Markets.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biopharmaceutical company undergoing dissolution and asset distribution processes.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Proprietary therapeutic products for gastrointestinal diseases are developed and marketed.
|
Locked | Locked | Locked |
Investor details for Merus Labs
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Merus Labs
Investment portfolio details for Merus Labs
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Merus Labs
Detailed financials for Merus Labs
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Merus Labs Comparisons
Peer comparison for Merus Labs
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Merus Labs
Detailed competitors of Merus Labs
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Merus Labs
Complete news archive for Merus Labs
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Merus Labs
Merus Labs was founded in 2009 and raised its 1st funding round 2 years after it was founded.
Merus Labs is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Merus Labs was established in 2009 in Toronto, Canada, within the pharmaceuticals sector. Corporate growth is pursued through an opportunistic product acquisition strategy. The portfolio encompasses Sintrom for thromboembolic conditions, Enablex for overactive bladder, Salagen for radiation-induced dry mouth, and Vancocin capsules for bacterial infections like C. difficile. Operations focus on sourcing and integrating these treatments for womens health, cancer, infectious, and cardiovascular areas.
Merus Labs has 3 investors. Key investors include Norgine, PDL BioPharma, and PowerOne Capital Markets.